Sarah Cannon Research Institute
@scri.com
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.
We’re expanding our collaboration with @bmsnews to accelerate cancer research and broaden access to clinical trials through SCRI’s Accelero model.
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
November 12, 2025 at 2:17 PM
We’re expanding our collaboration with @bmsnews to accelerate cancer research and broaden access to clinical trials through SCRI’s Accelero model.
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
November 7, 2025 at 5:59 PM
November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
October 9, 2025 at 7:35 PM
Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
October 6, 2025 at 6:08 PM
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
October 2, 2025 at 5:14 PM
At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
September 29, 2025 at 2:32 PM
Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Mary is proof that hope and research go hand in hand.
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
September 25, 2025 at 10:13 PM
Mary is proof that hope and research go hand in hand.
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co...
#AML #SCRI #ClinicalTrials #Hope
#AML #SCRI #ClinicalTrials #Hope
September 2, 2025 at 1:00 PM
Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co...
#AML #SCRI #ClinicalTrials #Hope
#AML #SCRI #ClinicalTrials #Hope
Kim’s story is a powerful reminder of what clinical trials can offer.
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
August 25, 2025 at 1:00 PM
Kim’s story is a powerful reminder of what clinical trials can offer.
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
Lisa’s story is one of resilience and research.
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
August 19, 2025 at 3:25 PM
Lisa’s story is one of resilience and research.
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
JP was diagnosed with stage IV lung cancer. He joined a clinical trial through SCRII at OHC—and responded to immunotherapy.
Now in remission, he celebrates each year with a cake and a message of hope. 🎂
#SCRI #CancerSurvivor #Immunotherapy #ClinicalResearch
www.scri.com/patients/?co...
Now in remission, he celebrates each year with a cake and a message of hope. 🎂
#SCRI #CancerSurvivor #Immunotherapy #ClinicalResearch
www.scri.com/patients/?co...
August 13, 2025 at 2:20 PM
JP was diagnosed with stage IV lung cancer. He joined a clinical trial through SCRII at OHC—and responded to immunotherapy.
Now in remission, he celebrates each year with a cake and a message of hope. 🎂
#SCRI #CancerSurvivor #Immunotherapy #ClinicalResearch
www.scri.com/patients/?co...
Now in remission, he celebrates each year with a cake and a message of hope. 🎂
#SCRI #CancerSurvivor #Immunotherapy #ClinicalResearch
www.scri.com/patients/?co...
💡 Why consider a clinical trial during your cancer journey?
✨ Access cutting-edge treatments
✨ Stay close to home
✨ Help shape the future of cancer care
🎥 Watch our latest video to learn more: www.scri.com/patients/
#CancerAwareness #ClinicalTrials #OncologyResearch #SCRI #HopeCloseToHome
✨ Access cutting-edge treatments
✨ Stay close to home
✨ Help shape the future of cancer care
🎥 Watch our latest video to learn more: www.scri.com/patients/
#CancerAwareness #ClinicalTrials #OncologyResearch #SCRI #HopeCloseToHome
July 30, 2025 at 6:50 PM
💡 Why consider a clinical trial during your cancer journey?
✨ Access cutting-edge treatments
✨ Stay close to home
✨ Help shape the future of cancer care
🎥 Watch our latest video to learn more: www.scri.com/patients/
#CancerAwareness #ClinicalTrials #OncologyResearch #SCRI #HopeCloseToHome
✨ Access cutting-edge treatments
✨ Stay close to home
✨ Help shape the future of cancer care
🎥 Watch our latest video to learn more: www.scri.com/patients/
#CancerAwareness #ClinicalTrials #OncologyResearch #SCRI #HopeCloseToHome
Thank you, #ASCO25!
We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration.
Here’s to advancing therapies for patients —together.
Until next year!
#SCRI #CancerResearch #OncologyLeadership #ThankYouASCO
We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration.
Here’s to advancing therapies for patients —together.
Until next year!
#SCRI #CancerResearch #OncologyLeadership #ThankYouASCO
June 5, 2025 at 3:18 PM
Thank you, #ASCO25!
We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration.
Here’s to advancing therapies for patients —together.
Until next year!
#SCRI #CancerResearch #OncologyLeadership #ThankYouASCO
We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration.
Here’s to advancing therapies for patients —together.
Until next year!
#SCRI #CancerResearch #OncologyLeadership #ThankYouASCO
Dr. Naqash serves as chair in the Oral Abstract Session: Lung Cancer-Non-Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session. #ASCO25
June 2, 2025 at 8:09 PM
Dr. Naqash serves as chair in the Oral Abstract Session: Lung Cancer-Non-Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session. #ASCO25
We look forward to seeing more of you on day four of the #ASCO25 Annual Meeting. Stop by both #27022 to meet experts from across the network, from 9:45am-2:00pm. #CancerResearch uberflip.scri.com/i/1535506-me...
June 2, 2025 at 12:55 PM
We look forward to seeing more of you on day four of the #ASCO25 Annual Meeting. Stop by both #27022 to meet experts from across the network, from 9:45am-2:00pm. #CancerResearch uberflip.scri.com/i/1535506-me...
Dr. Johnson tackled how community oncology can deliver cutting-edge lung cancer therapies:
🔹 Not all bispecifics need inpatient care
🔹 Tarlatamab = outpatient-friendly
🔹 Innovative care models = better access
#LungCancer #Immunotherapy #SCRI #ASCO25
🔹 Not all bispecifics need inpatient care
🔹 Tarlatamab = outpatient-friendly
🔹 Innovative care models = better access
#LungCancer #Immunotherapy #SCRI #ASCO25
June 1, 2025 at 6:35 PM
Dr. Johnson tackled how community oncology can deliver cutting-edge lung cancer therapies:
🔹 Not all bispecifics need inpatient care
🔹 Tarlatamab = outpatient-friendly
🔹 Innovative care models = better access
#LungCancer #Immunotherapy #SCRI #ASCO25
🔹 Not all bispecifics need inpatient care
🔹 Tarlatamab = outpatient-friendly
🔹 Innovative care models = better access
#LungCancer #Immunotherapy #SCRI #ASCO25
🔬 At #ASCO25, Dr. Naqash explored the promise & challenges of bispecific T-cell engagers (BiTEs) in lung cancer & beyond:
✅ Tarlatamab earns FDA nod for SCLC
⚠️ CRS & ICANS toxicity management is key
🎯 DLL3 & other targets may expand BiTE reach
#Immunotherapy #LungCancer #SCRI
✅ Tarlatamab earns FDA nod for SCLC
⚠️ CRS & ICANS toxicity management is key
🎯 DLL3 & other targets may expand BiTE reach
#Immunotherapy #LungCancer #SCRI
June 1, 2025 at 4:39 PM
🔬 At #ASCO25, Dr. Naqash explored the promise & challenges of bispecific T-cell engagers (BiTEs) in lung cancer & beyond:
✅ Tarlatamab earns FDA nod for SCLC
⚠️ CRS & ICANS toxicity management is key
🎯 DLL3 & other targets may expand BiTE reach
#Immunotherapy #LungCancer #SCRI
✅ Tarlatamab earns FDA nod for SCLC
⚠️ CRS & ICANS toxicity management is key
🎯 DLL3 & other targets may expand BiTE reach
#Immunotherapy #LungCancer #SCRI
At #ASCO25, Dr. @ErikaHamilton9 presented Phase 3 VERITAC-2 results:
🧬 Vedegestrant (first PROTAC ER degrader) showed:
✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC)
✅ Favorable safety (<5% AEs led to dose changes)
⏳ OS data maturing
A promising new option!
🧬 Vedegestrant (first PROTAC ER degrader) showed:
✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC)
✅ Favorable safety (<5% AEs led to dose changes)
⏳ OS data maturing
A promising new option!
May 31, 2025 at 9:01 PM
At #ASCO25, Dr. @ErikaHamilton9 presented Phase 3 VERITAC-2 results:
🧬 Vedegestrant (first PROTAC ER degrader) showed:
✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC)
✅ Favorable safety (<5% AEs led to dose changes)
⏳ OS data maturing
A promising new option!
🧬 Vedegestrant (first PROTAC ER degrader) showed:
✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC)
✅ Favorable safety (<5% AEs led to dose changes)
⏳ OS data maturing
A promising new option!
Dr. Frangoul and patient, Jimi, take the stage in a powerful #AACR/#ASCO joint session, showcasing both side of what it means to explore real-world gene therapy: successes, challenges & equitable access. #ASCO25
May 31, 2025 at 6:47 PM
Dr. Frangoul and patient, Jimi, take the stage in a powerful #AACR/#ASCO joint session, showcasing both side of what it means to explore real-world gene therapy: successes, challenges & equitable access. #ASCO25
Dr. Skip Burris, President of #SCRI, takes the stage to honor this year’s Top Donors—recognizing the individuals and organizations driving progress in cancer research and care.
Grateful for those fueling the future of oncology. #ASCO25 #CancerResearch #ASCOOpeningSession
Grateful for those fueling the future of oncology. #ASCO25 #CancerResearch #ASCOOpeningSession
May 31, 2025 at 4:13 PM
Dr. Skip Burris, President of #SCRI, takes the stage to honor this year’s Top Donors—recognizing the individuals and organizations driving progress in cancer research and care.
Grateful for those fueling the future of oncology. #ASCO25 #CancerResearch #ASCOOpeningSession
Grateful for those fueling the future of oncology. #ASCO25 #CancerResearch #ASCOOpeningSession
Live from #ASCO25! 🔬 Dr. Patt shared how ASCO is leveraging AI with Google Cloud to enhance decision support & pt care.🩸 Dr. Andorsky unveiled promising interim results on asciminib for CML-CP after one TKI.
#OncologyAI #CancerCare #CML
#OncologyAI #CancerCare #CML
May 30, 2025 at 8:53 PM
Live from #ASCO25! 🔬 Dr. Patt shared how ASCO is leveraging AI with Google Cloud to enhance decision support & pt care.🩸 Dr. Andorsky unveiled promising interim results on asciminib for CML-CP after one TKI.
#OncologyAI #CancerCare #CML
#OncologyAI #CancerCare #CML